|Bid||0.5600 x 900|
|Ask||0.5897 x 1800|
|Day's range||0.5623 - 0.5897|
|52-week range||0.5000 - 4.8000|
|Beta (5Y monthly)||0.94|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
We feel now is a pretty good time to analyse Evoke Pharma, Inc.'s ( NASDAQ:EVOK ) business as it appears the company...
Evoke Pharma, Inc. (EVOK) delivered earnings and revenue surprises of -125.00% and -98.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?